Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal TBK1 Primary Antibody for EIA, IF - ABIN500308
Pomerantz, Baltimore: NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. in The EMBO journal 2000
Show all 5 references for ABIN500308
Human Polyclonal TBK1 Primary Antibody for EIA, IHC (p) - ABIN360254
Deng, Shi, Han, Zhong, Li, Li, Hu, Yan, Wang, He, Tang, Deubel, Luo, Ning, Sun: Negative regulation of virus-triggered IFN-beta signaling pathway by alternative splicing of TBK1. in The Journal of biological chemistry 2008
Show all 3 references for ABIN360254
Human Monoclonal TBK1 Primary Antibody for WB - ABIN967614
Kishore, Huynh, Mathialagan, Hall, Rouw, Creely, Lange, Caroll, Reitz, Donnelly, Boddupalli, Combs, Kretzmer, Tripp: IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2. in The Journal of biological chemistry 2002
Show all 2 references for ABIN967614
Human Polyclonal TBK1 Primary Antibody for WB - ABIN2785953
Morton, Hesson, Peggie, Cohen: Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma. in FEBS letters 2008
TBK1 should thus also be sequenced, after exclusion of C9orf72 (show C9ORF72 Antibodies) mutation, in patients presenting frontotemporal dementia, particularly in cases secondarily associated with amyotrophic lateral sclerosis
TBK1 carriers with amyotrophic lateral sclerosis had shorter disease duration than carriers with frontotemporal dementia in a Belgian cohort.
The expression of TBK1 in mammalian cell mitosis is reported, including localization of the protein during division and its binding properties.
Optineurin (show OPTN Antibodies) and TANK-binding kinase 1 (TBK1) are transiently recruited to the polyubiquitinated mitochondria, and the activated TBK1 phosphorylates p62 (show GTF2H1 Antibodies) at S403
TBK1 loss of function mutations are the third most frequent cause of clinical frontotemporal dementia in a Belgian cohort.
Data suggest OPTN (optineurin (show OPTN Antibodies)) is involved in up-regulation of innate immunity in mitosis; mechanism involves phosphorylation/mitochondrial translocation of TBK1 and phosphorylation/nuclear translocation of CYLD (show CYLD Antibodies) (cylindromatosis protein).
TBK1 has a role in regulating T-cell activation and migration
Loss-of-function variants in OPTN (show OPTN Antibodies) and TBK1 are associated with clinical and pathological frontotemporal dementia without motor neuron disease; TBK1 mutations are common cause of frontotemporal lobar degeneration with TAR DNA-binding protein 43 (show TARDBP Antibodies) inclusions
findings demonstrate a novel regulatory circuit in which STING and TBK1 reciprocally regulate each other to enable efficient antiviral signaling activation, and PPM1A (show PPM1A Antibodies) dephosphorylates STING and TBK1
Data indicate that suppressor of cytokine signaling 3 (SOCS3 (show SOCS3 Antibodies)) knockdown markedly increases the abundance of TANK-binding kinase 1 (TBK1).
Data show that the formation of a tripartite ribosomal protein S6 kinase 1 (S6K1 (show RPS6KB1 Antibodies))-STING membrane protein-TANK-binding kinase 1 (TBK1) complex was necessary for the activation of interferon regulatory factor-3 (IRF3 (show IRF3 Antibodies)).
This study suggest that TBK1 exerts pronociceptive effects in inflammatory nociception which are due to both modulation of NF-kappaB dependent genes and regulation of MAPKs and c-fos.
TRIM27 (show RFP Antibodies) inhibits VSV infection-induced type I IFN production by promoting TBK1 degradation.
Suggest that by reducing production of cAMP in adipocytes, PDE3B (show PDE3B Antibodies), IKKepsilon (show IKBKE Antibodies) and TBK1 may contribute to the repression of energy expenditure during obesity.
our results identify CK2 (show CSNK2A1 Antibodies) as a novel regulator of TBK1 and IRF3 (show IRF3 Antibodies) and suggest that targeting CK2 (show CSNK2A1 Antibodies) by small molecular inhibitor may be a viable approach to prevent and treat viral infections.
A role for APPL1 (show APPL1 Antibodies) in TLR3 (show TLR3 Antibodies)/4-dependent TBK1 and IKKepsilon (show IKBKE Antibodies) activation in macrophages.
The results highlight the importance of the C-terminal region in the functional activity of IKKepsilon (show IKBKE Antibodies) in innate immune response.Interestingly, corresponding region and residues are not required for activation of downstream signaling by TBK1.
data elucidated the cell type-specific subcellular localization of p-TBK1 and a cell type-specific role of IPS-1 (show ISYNA1 Antibodies) in TBK1 activation in response to cytoplasmic viral DNA.
The NF-kappa-B (NFKB) complex of proteins is inhibited by I-kappa-B (IKB) proteins, which inactivate NFKB by trapping it in the cytoplasm. Phosphorylation of serine residues on the IKB proteins by IKB kinases marks them for destruction via the ubiquitination pathway, thereby allowing activation and nuclear translocation of the NFKB complex. The protein encoded by this gene is similar to IKB kinases and can mediate NFKB activation in response to certain growth factors.
serine/threonine-protein kinase TBK1
, TANK-binding kinase 1
, NF-kappa-B-activating kinase
, TANK binding kinase 1
, serine/threonine protein kinase TBK1
, serine/threonine-protein kinase TBK1-like
, NF-kB-activating kinase